about
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesAdvances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumorsContemporary murine models in preclinical astrocytoma drug developmentEcto-5'-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma ModelSubgroup-specific structural variation across 1,000 medulloblastoma genomesG-protein coupled receptor expression patterns delineate medulloblastoma subgroupsCooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.In vivo Mn-enhanced MRI for early tumor detection and growth rate analysis in a mouse medulloblastoma model.Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review.Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.Actionable molecular biomarkers in primary brain tumors.Chromatin-regulating proteins as targets for cancer therapy.Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.Brain neoplasms and coagulation-lessons from heterogeneity.A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression.Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours.Drugging Hedgehog: signaling the pathway to translation.Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastomaPemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells featuresGene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesisSerpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-propertiesCCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastomaMolecular markers in pediatric neuro-oncology.Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cellsAdvances in paediatric cancer treatmentRelapsed High-Risk Medulloblastoma: Stable Disease after Two Years of Treatment with Somatostatin Analog - Case Report.Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.MRI surrogates for molecular subgroups of medulloblastoma.Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.Signaling pathway and molecular subgroups of medulloblastoma.Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.
P2860
Q26741529-379FE7AF-0BE4-43C4-81C0-65451AAA2E25Q26820289-676904C6-E80D-4E6E-B6BF-EDDF45654091Q26866408-C0AB10EC-40A7-491C-90D0-23A16599A9C6Q27026937-C6FEA683-6E74-45D7-B870-7DA4A8DFF01DQ27312282-A779D494-FFF4-45A5-981B-D8DF2CC604C1Q28271811-42BA7955-4A26-4824-B202-8BDEDDF11726Q28302285-07BBD192-8762-4D1C-B3A9-1F4C4101E33BQ30545759-4EEF2A6A-770B-4BC5-B9A4-2C42DB7F9C7EQ30618694-A1385C74-CC58-462E-AA2E-D45669EE277CQ30764536-C450A42C-E1E8-493C-A776-7170DEE123F2Q33633473-04CD9F36-7B4E-4AF6-BB91-0B1C68A7BF13Q33756997-64F51E8C-098E-4372-9AD0-65003FA13BFFQ33772355-D74A9F0E-CF26-4DB4-8D3C-9E44F3909BD6Q33907067-2B73C047-645B-4E9B-BFBF-2A935DECDC78Q33907955-F330B473-77BB-401E-99DE-467CE6E17165Q34285237-7ED26545-C273-44A3-95F4-873927F6BE99Q34463432-AC1574E1-3693-4D0D-82F0-EF38AEA20A0DQ34486255-86BD3BA1-2194-4B05-A3A6-23C51525EDBEQ34553348-F293C7D4-9DA7-434F-98D7-6EF68262DFDDQ34625129-28F8BC8A-B7DD-4E94-81A9-6FD3ED7895AAQ34669248-EE4FAF5C-496F-4FDC-8C31-DCAF0FC8FDC8Q34978358-3F049130-0714-47D4-87EC-DD73AF0537A4Q35100720-63977003-AE77-4475-8933-C93705E7C2BBQ35135650-0AAB6705-05F9-43D1-BDDE-70B4E61FF004Q35150189-BDDBFB75-99DF-4CED-B6D7-8094B9E63192Q35440212-C8DBDE9A-03E4-44FB-8441-0CC35021B12FQ35611341-FB5C6D41-5528-462C-BEE5-2D18E397A181Q35788820-CCAA99BA-639F-4294-B1E1-B0FD2F80AD3CQ35925281-75F92842-F360-45CE-84F7-30DF53F5683CQ36118149-9687D9C2-3E44-4432-B0B5-075D8A1DE791Q36344704-52BB1CC4-771F-4EC4-ACBE-E4F145253621Q36377759-A5D08F6C-EE69-4AF3-944B-E517359AAED9Q36508630-77F94F6E-0587-4703-94A2-27619790B2FEQ36552290-E93B26C9-D3B3-4F99-B46B-F28373D91995Q36627160-9CB7575E-2745-4083-9548-BB5407640734Q36760167-45C8FFBB-411F-478B-9A65-72896CC862FCQ36929844-74B99CBE-3745-4944-B5D8-68E066F7E97EQ36956174-5BE86130-C164-4B3F-A300-A463C00BF0FBQ37004219-3FA7EB42-72AD-4189-8C48-EEA30221A3E3Q37006613-219E1BD2-3931-487A-A9B2-B6296BBE027D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The clinical implications of medulloblastoma subgroups.
@en
type
label
The clinical implications of medulloblastoma subgroups.
@en
prefLabel
The clinical implications of medulloblastoma subgroups.
@en
P2093
P2860
P356
P1476
The clinical implications of medulloblastoma subgroups.
@en
P2093
Andrey Korshunov
Michael D Taylor
Paul A Northcott
P2860
P2888
P304
P356
10.1038/NRNEUROL.2012.78
P407
P577
2012-05-08T00:00:00Z
P6179
1025875930